ClinicalTrials.gg
Drug

Rezvilutamide clinical trials

Also written SHR3680.

studies test it
24
open now
12
in phase 3
4
first study started
2016

How each study uses rezvilutamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the rezvilutamide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Rezvilutamide
6
Rezvilutamide Tablets
2

Development codes

SHR3680
9

Studies by the year they started

24 studies that test it; most in 2023 (8)

Studies that test rezvilutamide, by start year
YearStudies
20162
20181
20191
20205
20213
20238
20241
20251
20262

By phase

A phase 1/2 study counts in both.

Phase 1
8
Phase 2
12
Phase 3
4
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 12

Jiangsu HengRui Medicine Co., Ltd. (11) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (4) · Fudan University (3) · Atridia Pty Ltd. (1) · Zhujiang Hospital (1) · Fujian Medical University Union Hospital (1) · Jianbin Bi (1) · Peking University First Hospital (1)

Often tested with

Tested in the same studies.

Fluzoparib (4) · Camrelizumab (2) · Trastuzumab rezetecan (1) · Tizetatug rezetecan (1) · Leuprolide (1) · Abiraterone Acetate (1) · Abiraterone (1) · Prednisolone (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Rezvilutamide is the comparator. A study of two new drugs counts under both.

  • 1Docetaxel · The First Affiliated Hospital with Nanjing Medical University
Reaching primary completion within a year · 7, 1 in phase 3

Studies that test rezvilutamide, phase 3 first.

Studies

Open first, then newest update. How each study uses rezvilutamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 24

See all 24 studies that test rezvilutamide →

Given beside what is tested · 5 — rezvilutamide is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with rezvilutamide

Codes

What other systems call rezvilutamide · ClinicalTrials.gg INT015360

  • UNII (FDA) 70FJN2AW22REZVILUTAMIDEConfirmed FDA, Wikidata
  • Wikidata Q101063961rezvilutamideConfirmed FDA, Wikidata
  • NCI Thesaurus C175852RezvilutamideOne source FDA
  • DrugBank DB19133One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.